Aurinia 2025 Q3 Earnings Net Income Surges 119.9% as Revenue and Guidance Rise

Aurinia Pharmaceuticals (AUPH) reported fiscal 2025 Q3 earnings on Nov 4, 2025, . . . , reflecting strong LUPKYNIS demand.

Revenue

. Net product sales, driven by LUPKYNIS, , while license, collaboration, .

Earnings/Net Income

, . This marked a record high for Q3 net income in 13 years, reflecting robust profitability. The significant EPS and net income growth underscores Aurinia’s strong operational performance and effective cost management.

Post-Earnings Price Action Review

Following the earnings release, , reflecting strong market confidence. . Analysts attribute the positive reaction to robust LUPKYNIS sales growth and raised guidance, though the Zacks Rank #3 (Hold) suggests caution for near-term performance.

CEO Commentary

CEO highlighted sustained LUPKYNIS sales momentum, driven by updated treatment guidelines, and optimism about aritinercept’s Phase 1 results. The company plans to advance aritinercept to clinical trials in two autoimmune diseases by year-end.

Guidance

, citing LUPKYNIS growth. Forward-looking risks include regulatory uncertainties and clinical timelines.

Additional News

Aurinia’s Phase 1 aritinercept trial, a dual BAFF/APRIL inhibitor, demonstrated tolerability and no severe adverse events, with plans to initiate trials in two autoimmune diseases by year-end. The CEO emphasized strategic confidence in therapeutic innovation and market positioning. Additionally, , though Zacks analysts caution that near-term performance may align with market benchmarks.